New Jersey’s reputation as the “Medicine Chest of the World” reached a new milestone Wednesday as Made Scientific, Inc., a leading Princeton-based cell therapy manufacturer, joined forces with partners in Israel and Florida to bring a revolutionary stem cell treatment to the U.S. market.
The three-way collaboration between Cytora Therapeutics (Tel Aviv), Made Scientific (Princeton), and Zeo ScientifiX (Davie, FL) aims to treat non-healing diabetic foot ulcers (DFUs) using a unique source of regenerative power: the human mouth.
At the center of this global deal is Made Scientific’s state-of-the-art, 60,000-square-foot facility in Princeton. Under the agreement, the New Jersey site will serve as the exclusive U.S. manufacturing hub, responsible for the Good Manufacturing Practice (GMP) production and quality control of the therapy.
The facility recently underwent a significant 12,000-square-foot expansion in 2025 to accommodate the high-throughput demands of late-phase and commercial-stage cell therapies. This infrastructure is critical for “allogeneic” or “off-the-shelf” treatments, which must be mass-produced with extreme precision to be ready for patient use immediately.
“This partnership exemplifies Made’s commitment to supporting innovative cell therapies from development through commercial supply,” Syed Husain, chairman and CEO of Made Scientific said. “Our integrated GMP manufacturing capabilities in Princeton are uniquely positioned to deliver this innovative therapy.”
The therapy utilizes human oral mucosal stem cells (hOMSCs). Unlike stem cells harvested from bone marrow or fat, these cells are gathered through minimally invasive procedures in the mouth—a region known for its extraordinary ability to heal rapidly without scarring.
Clinical highlights of the hOMSC therapy include:
-
Proven Success: In Phase 1/2a trials, patients with chronic ulcers open for an average of 27 months saw complete wound closure.
-
Rapid Response: The cells promote faster re-epithelialization and the formation of healthy new tissue.
-
Safety: No serious adverse events were reported during initial clinical testing.
The partnership is moving on two fronts to ensure patients can access the treatment as quickly as possible:
-
Florida Commercialization: Leveraging Florida’s recently passed stem cell law (SB 1768), which allows for the use of compliant, non-FDA-approved therapies for specific conditions like wound care and pain.
-
Federal Approval: Simultaneously launching U.S. FDA Phase 2b clinical trials with the goal of securing a formal national license.
The expansion of Made Scientific’s operations in Princeton and its secondary training center in Newark continues to fuel New Jersey’s life sciences boom. The state’s lab space is projected to increase by 27% by the end of 2026, driven by high-tech manufacturing deals like this one.
For the estimated 125,000 new diabetic foot ulcer patients diagnosed annually in Florida alone—and millions more nationwide—this Jersey-made therapy offers a long-awaited alternative to traditional treatments and potential amputations.
